Hwang chul soon biography of albert einstein
Abstract
PURPOSE
Non–small-cell lung cancer (NSCLC) with STK11 has inferior outcomes to immune checkpoint inhibitors (ICIs). Using multiomics, we evaluated whether a subtype of STK11 NSCLC with a uniquely inflamed tumor immune microenvironment (TIME) harboring TP53 comutations could have favorable outcomes to ICIs.
PATIENTS AND METHODS
NSCLC tumors (N = 16,896) were analyzed by next-generation sequencing (DNA-Seq/592 genes). A subset (n = 5,034) underwent gene expression profiling (RNA-Seq/whole transcriptome). Exome-level neoantigen load for STK11 NSCLC was obtained from published pan-immune analysis. Tumor immune cell content was obtained from transcriptome profiles using the microenvironment cell population (MCP) counter. ICI data from POPLAR/OAK (n = 34) and the study by Rizvi et al (n = 49) were used to model progression-free survival (PFS), and a separate ICI-treated cohort (n = 53) from Dana-Farber Cancer Institute (DFCI) was used to assess time to treatment failure (TTF) and tumor RECIST response for STK11TP53 versus STK11TP53 NSCLC.
RESULTS
Overall, 12.6% of NSCLC tumors had a STK11 with the proportions of tumor mutational burden (TMB)-high (≥10 mut/Mb), PD-L1 ≥50%, and microsatellite instability-high being 38.3%, 11.8%, and 0.72%, respectively. Unsupervised hierarchical clustering of STK11 (n = 463) for stimulator of interferon-gamma (STING) pathway genes identified a STING-high cluster, which was significantly enriched in TP53 NSCLC (P < .01). Compared with STK11TP53, tumors with STK11TP53 had higher CD8+T cells and natural killer cells (P < .01), higher TMB (P < .001) and neoantigen load (P < .001), and increased expression of MYC and HIF-1A (P < .01), along with higher expression (P < .01) of glycolysis/glutamine metabolism genes. Meta-analysis of data from OAK/POPLAR and the study by Rizvi et al showed a trend t Last month, I spent four vacation days in New Orleans (Louisiana). As you know, New Orleans is the origin of American music or American rhythm. When I was there, there were more than 5,000 country boys and girls who came all the way from Green Bay (Wisconsin) to cheer their football team named "Green Bay Packers" (you should know this name if you lived in the U.S. for two years or longer). You could imagine how noisy or rhythmic the city was. However, the rhythm most familiar to me was from the bottom of the New Orleans trolley car. It was coming from the air compressor for the brake system. As soon as I heard the rhythm, I looked at the driver's stand. Alas, the stand consists of the speed controller contained in an elliptic cylindrical box on the left-hand side, the air-brake valve supported by three pipes on the right hand-side, and the circuit breaker hanging between the ceiling and the front window on the left-hand side. The driver's stand was exactly like that of Seoul's trolley cars which served as wonder machines to Koreans for 60 years until 1963. Indeed, Seoul's Electric Car meant many different things to many different Koreans. Near my high school, there were two elite girl's high schools. Thus, for me, the Electric Car was the place to watch neat-looking girls while going to school in the morning and going home in the afternoon. For mothers in the country side, their life-time dream was to make their sons the Electric Car drivers. There were many boys from the Cheju Island in the Korean Marine Corps in 1950. When they entered Seoul after repulsing Kim Il-sung's troops on September 28 (1950), they rubbed their cheeks against the walls of the Seoul Electric Cars. Most of Seoul's Electric Cars were manufactured by Japan's Mitsubishi, and its trade mark was on the top of the speed-controller box. The Car had six doors with two irreversible trolleys. It had a co Dr. C. Justin Lee is currently a Tenured Research Scientist, serving as the Co-Director of Center for Cognition and Sociality at IBS. He has received his PhD at Columbia University in Physiology and Cellular Biophysics and bachelor degree at University of Chicago in Chemistry. He has been a leading neuroscientist researching on the subject of astrocytes, whose functions have recently been re-evaluated in numerous reports. Particularly, he has focused on astrocytes’ ability to release various transmitters (termed gliotransmitters) including glutamate, d-serine, ATP, and GABA. He discovered that astrocytes in the cerebellum produce and release GABA through MAO-B enzyme and Bestrophin-1 channel, respectively. He also demonstrated the detailed molecular mechanisms of how astrocytes release glutamate upon GPCR activation. He went on to demonstrate that the astrocytic GABA in hippocampus impairs memory in Alzheimer’s disease. His work continues to impact the field of brain research by providing novel molecular mechanisms for glia-neuron interaction. These new findings are actively applied to the field of neuropsychiatric disorders and neurodegenerative diseases, promising novel drug targets for the treatment of various neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. He has published a total of 130 papers with H-Index of 38 (total citations of 5091 as of March 2018) in major scientific journals including Nature Medicine (2014), Nature Communications (2014), Cell (2012) and Science (2010). He also received numerous prestigious awards including Kyung Ahm Prize in Arts and Sciences, 2016, FILA Basic Science Award (The Korean Academy of Science and Technology, 2014), Jang Jin Award (Korean Brain and Neuroscience Society, 2014), and Star Professor Award (The University of Science and Technology, 2013) The aim of this study is to investigate the clinical validity of donor-derived cell-free DNA (dd-cfDNA) in comparison with that of donor specific anti-HLA antibody (DSA) for predicting biopsy-proven rejection (BPR)and severe microvascular inflammation (severe MVI) in kidney transplant recipients (KTRs). In this prospective observational investigation, 64 KTRs who underwent the indicated biopsies were included. Blood samples collected prior to biopsy were tested for dd-cfDNA and DSA. Biopsy specimens were classified by a renal pathologist according to the Banff classification. The predictive performance of dd-cfDNA and DSA for histological allograft diagnosis was assessed. KTRs were categorized into the high and low dd-cfDNA groups based on a level of 0.4%. Eighteen patients (28.1%) had positive DSA at biopsy, exhibiting higher dd-cfDNA levels than the DSA-negative patients. BPR and severe MVI incidences were elevated in the high dd-cfDNA group (BPR: 42.9% vs. 3.4%, P <0.001; severe MVI: 37.1% vs. 3.4%, P = 0.001). Also, elevated glomerulitis and MVI scores were observed in the high dd-cfDNA group. DSA showed the highest predictive value for BPR (AUC = 0.880), whereas dd-cfDNA alone excelled in predicting severe MVI (AUC = 0.855). Combination of DSA and dd-cfDNA (>0.4%) yielded sensitivities of 80.0% and 50.0% with specificities of 90.7% and 88.0% for antibody-mediated rejection and severe MVI detection, respectively. The dd-cfDNA test is a predictive tool for BPR and severe MVI, and it can improve the performance, especially when combined with DSA for BPR. Keywords: kidney transplantation, cell-free nucleic acids, allograft rejection, microvascular rejection, tissue donors Kidney transplantation (KT) is the most ideal modality for the treatment of end stage renal disease (ESRD) patients (1). However, allograft rejection is still an important obstacle for successful long-term maint Wisdom of Korea (1996, January -- June)
SEOUL'S OLD RHYTHM
Y.S.Kim (1996.1.8) Editor-in-Chief
Deputy Editors
Abstract
Introduction
Methods
Results
Conclusion
1. Introduction